Chongqing Pharmaceutical Holdings: Announcement on back payment of taxes

Securities code: 000950 Securities abbreviation: Chongyao Holdings Announcement number: 2026-005

Chongyang Pharmaceutical Holdings Co., Ltd.

Announcement on back payment of taxes

The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and contains no false records, misleading statements or major omissions.

1. Basic situation

The subsidiaries of Chongqing Pharmaceutical Holdings Co., Ltd. (hereinafter referred to as the "Company") include Qinghai Pharmaceutical Co., Ltd., Chongqing Pharmaceutical Holdings Zhelimumeng Pharmaceutical (Inner Mongolia) Co., Ltd., Guizhou Pharmaceutical (Group) Co., Ltd., Guizhou Pharmaceutical (Group) Heping Pharmaceutical Co., Ltd., Shaanxi Huashi Pharmaceutical Co., Ltd., Chongqing Pharmaceutical Holdings Shaanxi Pharmaceutical Co., Ltd., Chongqing Pharmaceutical Group (Gansu) Co., Ltd., a total of 7 companies, according to the notices of their respective competent tax authorities, need to make up for the preferential corporate income tax and late payment fees they enjoyed in the early stage of the Western Development after self-examination, totaling 32.2103 million yuan, of which the amount of backpayment in 2025 is 7.458 million yuan, and the backpayment amount in 2026 is 24.7523 million yuan. As of the disclosure date of this announcement, the above-mentioned taxes and late fees have been paid in full, and the competent tax authorities have not imposed any penalties on this matter.

2. Impact on the company

According to the "Accounting Standards for Business Enterprises No. 28 - Accounting Policies, Changes in Accounting Estimates and Correction of Errors", the above back payment of taxes and late payment fees are not accounting errors in the previous period and do not involve retrospective adjustments to financial data in the previous period. The company's back payment of the above taxes and late fees will be included in the current profits and losses in 2025 and 2026 respectively. The specific impact on the company's net profit attributable to shareholders of listed companies in 2025 and 2026 will ultimately be based on the company's audited financial statements for 2025 and 2026.

This back payment of taxes will not affect the company's normal operations. Investors are advised to pay attention to investment risks.

Announcement hereby

Board of Directors of Chongyang Pharmaceutical Holdings Co., Ltd.

January 23, 2026